Oral Wegovy May Work Best for Recently Gained Weight, Mouse Study Explains Allergy Spread

People who have put on weight in recent years may respond especially well to the pill form of Novo Nordisk's Wegovy, according to an early analysis of real-world data.

Researchers reviewed records for 3,011 patients prescribed oral Wegovy who had a follow-up weight recorded within 180 days. None had used other GLP-1 medicines before. Those whose weight gain was recent were far more likely to become "super-responders" — patients who lost more than 10% of their starting body weight during treatment.

Study leader Venky Soundararajan of the data analytics firm nference said the pattern held across ages: whether a person was 30, 60 or 90 and had gained significant weight in the past five years, they were far more likely to reverse that gain within months than someone whose weight had climbed over a longer period.

Super-responders also weighed less at the start of treatment, averaging 207 pounds (94.1 kg) against 224.21 pounds (101.7 kg) for non-responders, and were more likely to have moved above the 1.5-milligram starting dose by day 60. As patients continued the pills, their blood pressure improved significantly, with the reductions tracking the amount of weight lost.

The authors caution that the findings, posted online and not yet peer-reviewed, do not prove cause and effect. They say the results justify more rigorous studies into whether a patient's pre-treatment weight trajectory predicts how well they will respond. Oral Wegovy was approved in the United States in December of last year.

Separately, a study in mice offers a possible explanation for two long-standing puzzles about allergies: why they often appear only after repeated exposure, and why people with one allergy frequently develop others.

Published in the journal Immunity, the work found that sensory neurons — nerve cells that carry signals such as itch and pain to the central nervous system — retain a "memory" of allergens. The team had previously shown that these neurons directly sense certain allergens and help set off the allergic immune response. The new study indicates the neurons do more than detect allergens in the moment: they keep a metabolically encoded record of earlier exposures, allowing a stronger response later even after the original allergen is gone.

"Neurons are known for their ability to form memories," study leader Dr. Caroline Sokol of Mass General Brigham in Boston said in a statement. "We asked whether an initial allergen exposure might leave a trace, not enough on its own to trigger a full allergic response, but enough to prime the neurons to respond more strongly the next time."

The researchers found that a first exposure activates a specific signaling pathway in neurons that primes them to react not only to the same allergen but also to others sharing the same enzymatic activity despite different molecular structures. That cross-allergen response may help explain why sensitivity to one substance can raise susceptibility to others.

"Now that we know what may cause people to become allergic and pick up more sensitivities, we can design ways to stop it from happening," Sokol said.